BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
路透社2026/10/09 04:26October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
October 9 - ** Goldman Sachs points out that India's 30% profit cap on off-schedule anti-cancer drug prices (link) has limited impact on hospitals
** The report states that initial discussions with hospital chain groups indicate such drugs account for less than 5% of hospital revenues and 2% to 2.5% of operating profit
** The report adds that hospitals can offset losses by slightly adjusting service prices, such as administration fees
** The government announcement states that an expert committee will finalize the list of drugs to be regulated
** Affected by the price cap expectation, shares of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had seen an accumulated drop of 11% to 11.5%
** Year to date, FOHE and MAXE are down 11.7% and 14.8% respectively, while APLH is up 11%
(To make it easier for non-English speakers, Reuters has automated the translation of its reports into several other languages. Since automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of this automated translation text and provides it solely for reader convenience. Reuters accepts no liability for any harm or loss arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Reports of iPhone production cuts send Apple shares lower
October 9 – According to Nikkei Asia (link), Apple has asked its suppliers to cut production of the new iPhone 18 Pro model due to weak demand, resulting in Apple (AAPL.O) shares falling 1.8% in premarket trading to $334.21. The report states that, against the backdrop of soaring memory chip costs and rising prices, the component orders for October have been reduced by at least 15% compared to initial requirements. Apple has not yet responded to a Reuters request for comment. The current stock price is about 1% lower than the all-time intraday high of $345.34 reached on September 22. According to data compiled by the London Stock Exchange Group (LSEG), the average rating from 43 analysts covering the stock is "Buy," with a median target price of $330. (For the convenience of non-English speakers, Reuters provides automated translations of its report into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss resulting from use of the automated translation function.)
Citi maintains a “Neutral” rating on DocuSign (DOCU.O): IAM platform migration shows initial effectiveness, double-digit growth still needs "validation"
Citi published a research report maintaining a "Neutral" rating on the e-signature and agreement cloud platform DocuSign, with a target price of $72.
Market Chatter: Mastercard CEO Says Cross-Border Payments Is Currently Stablecoin's Best Use Case
07:14 AM EDT, 10/09/2026 (MT Newswires) -- Mastercard (MA) Chief Executive Officer Michael Miebach said that cross-border payments currently present the best use case for stablecoins, Bloomberg reported Friday, citing an interview. Mastercard is interested in stablecoins for moving money rather than as an investment, Miebach said, according to the report. The company is an investor in a new firm called Open Standard, which recently issued a US dollar-pegged stablecoin, the report added. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Humana shares soar as it becomes the biggest beneficiary of the 2027 Medicare star ratings.
Reuters, October 9 – In pre-market trading on Friday, shares of Humana (stock code: HUM.N) rose by 15%. Analysts said the health insurer is set to be the biggest beneficiary of the new 2027 Medicare Advantage star ratings. Humana stated that, with improvements in healthcare quality and member experience indicators, 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher by 2027, a substantial jump from 20% in 2026 (link). JPMorgan analysts noted that they had previously projected this ratio to be between 60% and 70%. The U.S. Department of Health and Human Services uses a one- to five-star scale to rate Medicare Advantage and prescription drug plans. Higher ratings lead to government bonuses worth billions of dollars and can help attract more members. Analysts noted that Humana’s ratings performance outpaced its larger competitors: JPMorgan expects the proportion of UnitedHealth Group’s (UNH.N) plans rated four stars or higher to decrease from 81% to about 67%, while CVS Health’s (CVS.N) ratio will fall from 84% to about 70%. The U.S. Department of Health and Human Services said Thursday night that, overall, about 71% (link) of Medicare Advantage prescription drug plan enrollees will be in contracts rated four stars or higher in 2027. Evercore ISI analyst Elizabeth Anderson said that Humana had improved in prescription drug plan quality, health plan quality, and readmission rates. She added, “This improvement reflects management’s increased focus on these metrics over the past year.” Health insurers provide Medicare Advantage plans for the government to adults aged 65 and older and people with disabilities.
Crypto prices
More
